ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14
LOS ANGELES, March 06, 2023 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, and its subsidiary Nexcella, Inc. (“Nexcella”), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that […]
ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14
LOS ANGELES, March 06, 2023 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, and its subsidiary Nexcella, Inc. (“Nexcella”), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that […]